[go: up one dir, main page]

NO308296B1 - Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel - Google Patents

Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel

Info

Publication number
NO308296B1
NO308296B1 NO972016A NO972016A NO308296B1 NO 308296 B1 NO308296 B1 NO 308296B1 NO 972016 A NO972016 A NO 972016A NO 972016 A NO972016 A NO 972016A NO 308296 B1 NO308296 B1 NO 308296B1
Authority
NO
Norway
Prior art keywords
same
neuropeptide
indolyl
medicament
manufacture
Prior art date
Application number
NO972016A
Other languages
English (en)
Other versions
NO972016D0 (no
NO972016L (no
Inventor
Thomas Charles Britton
Jr Robert Frederick Bruns
Donald Richard Gehlert
Philip Arthur Hipskind
Karen Lynn Lobb
James Arthur Nixon
Paul Leslie Ornstein
Edward C R Smith
Hamideh Zarrinmayeh
Dennis Michael Zimmermann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523999.2A external-priority patent/GB9523999D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO972016D0 publication Critical patent/NO972016D0/no
Publication of NO972016L publication Critical patent/NO972016L/no
Publication of NO308296B1 publication Critical patent/NO308296B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO972016A 1995-09-01 1997-04-30 Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel NO308296B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US315095P 1995-09-01 1995-09-01
GBGB9523999.2A GB9523999D0 (en) 1995-11-23 1995-11-23 Indolyl neuropeptide y receptor antagonists
US2163896P 1996-07-12 1996-07-12
PCT/US1996/014163 WO1997009308A1 (en) 1995-09-01 1996-08-30 Indolyl neuropeptide y receptor antagonists

Publications (3)

Publication Number Publication Date
NO972016D0 NO972016D0 (no) 1997-04-30
NO972016L NO972016L (no) 1997-06-17
NO308296B1 true NO308296B1 (no) 2000-08-28

Family

ID=27267993

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972016A NO308296B1 (no) 1995-09-01 1997-04-30 Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel

Country Status (14)

Country Link
EP (1) EP0789688A4 (no)
CN (1) CN1173867A (no)
AU (1) AU717422B2 (no)
BR (1) BR9606619A (no)
CA (1) CA2203912A1 (no)
CZ (1) CZ132897A3 (no)
HU (1) HUP9701714A3 (no)
IL (1) IL120724A0 (no)
MX (1) MX9703186A (no)
NO (1) NO308296B1 (no)
NZ (1) NZ318228A (no)
PL (1) PL320010A1 (no)
TR (1) TR199700334T1 (no)
WO (1) WO1997009308A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729590B2 (en) * 1996-10-23 2001-02-08 Sanofi-Aventis Cosmetic composition containing a neuropeptide Y receptor antagonist
CA2286660A1 (en) * 1997-04-16 1998-10-22 Arqule, Inc. Synthesis and use of .alpha.-ketoamide derivatives and arrays
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6200990B1 (en) * 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
EP1184373A4 (en) 1999-04-20 2004-10-20 Meiji Seika Kaisha TRICYCLIC CONNECTIONS
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
EP1254115A2 (en) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2001066110A2 (en) * 2000-03-09 2001-09-13 Eli Lilly And Company METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
ATE479655T1 (de) 2001-09-14 2010-09-15 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
CA2473803A1 (en) 2002-02-01 2003-08-07 Robert Greenhouse Substituted indoles as alpha-1 agonists
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05006288A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados del acido 3-carbonil-1h-indol-1-ilacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
ES2311755T3 (es) * 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
ATE462432T1 (de) 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US7323483B2 (en) 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
BRPI0614340A2 (pt) 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso
WO2007046112A1 (en) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Arylthioether tryptamine derivatives as functional 5-ht6 ligands
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2010013602A (es) 2008-06-19 2011-03-15 Takeda Pharmaceuticals Co Compuesto heterociclico y uso del mismo.
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
PT2707101T (pt) * 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
WO2012168697A1 (en) 2011-06-06 2012-12-13 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
CN104829465B (zh) * 2015-02-13 2018-04-27 普济生物科技（台州）有限公司 一种4-异丙氨基-1-丁醇的制备方法
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN111377821A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种合成4-异丙氨基-1-丁醇的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
US5264420A (en) * 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
EP0639567A1 (en) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Indole derivative
TW270114B (no) * 1993-10-22 1996-02-11 Hoffmann La Roche
AU3953795A (en) * 1994-10-20 1996-05-15 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists

Also Published As

Publication number Publication date
EP0789688A1 (en) 1997-08-20
PL320010A1 (en) 1997-09-01
HUP9701714A2 (hu) 1999-06-28
AU717422B2 (en) 2000-03-23
CZ132897A3 (en) 1997-11-12
NZ318228A (en) 1999-07-29
WO1997009308A1 (en) 1997-03-13
BR9606619A (pt) 1997-12-23
IL120724A0 (en) 1997-08-14
TR199700334T1 (tr) 1997-08-21
MX9703186A (es) 1997-07-31
CN1173867A (zh) 1998-02-18
AU6965096A (en) 1997-03-27
CA2203912A1 (en) 1997-03-13
NO972016D0 (no) 1997-04-30
HUP9701714A3 (en) 2000-03-28
EP0789688A4 (en) 1997-11-19
NO972016L (no) 1997-06-17

Similar Documents

Publication Publication Date Title
NO308296B1 (no) Indolyl neuropeptid Y reseptorantagonister, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av legemiddel
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
DE69525148D1 (de) Pharmazeutische formulierung
NO961136D0 (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
HUP9901092A3 (en) Benzimidazole compounds and their pharmaceutical use
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
NO305907B1 (no) Forbindelser, forbindelser for bekjempelse av sykdommer, legemidler som endotelinreseptorantagonist, farmasöytiske preparater samt anvendelse av slike forbindelser til fremstilling av legemidler
NO981008D0 (no) Farmasöytisk formulering
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
ID16742A (id) Antagonis reseptor endotelin
NO305906B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
NO306113B1 (no) Adhesjonsreseptorantagonister, farmasöytiske preparater som inneholder slike forbindelser, samt anvendelse av forbindelsene til fremstilling av legemidler
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
FI973230A0 (fi) Uusi farmaseuttinen formulaatio
DE69715247D1 (de) Auf quinupristin und dalfopristin basierte stabilisierte pharmazeutische zusammensetzung, und deren zubereitung
NO307737B1 (no) Anvendelse av neurotensin-antagonister for fremstilling av diuretiske medikamenter
NO20003393D0 (no) FremgangsmÕte for fremstilling av en farmasøytisk formulering
BR9606066A (pt) Composto e formulação farmacêutica
DE19681529D2 (de) Pharmazeutische Darreichungsform
NO304230B1 (no) Piperazinforbindelse, medikament og farmas°ytisk preparat omfattende denne

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN FEBRUARY 2002